XCELLSYZ IDENTIFIES MECHANISM OF ACTION OF XD4241 COMPOUND.Xcellsyz Ltd, Newcastle, UK, a company focused on the discovery of new drugs for diabetes and obesity through the use of novel cell-based technologies, has identified the mechanism of action of its lead antidiabetic compound XD4241. The molecular target of the XD4241 has been identified as Glycogen Synthase synthase /syn·thase/ (-thas) a term used in the names of some enzymes, particularly lyases, when the synthetic aspect of the reaction is dominant or emphasized. syn·thase n. Kinase-3 (GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) 3) a key enzyme involved in the regulation of glycogen glycogen (glī`kəjən), starchlike polysaccharide (see carbohydrate) that is found in the liver and muscles of humans and the higher animals and in the cells of the lower animals. metabolism. Prof. Peter Shepherd, CSO (Chief Security Officer) The person in charge of all staff members who are responsible for promulgating, enforcing and administering security policies for all systems within an enterprise or division. and co-founder of Xcellsyz said, "This is an important milestone in the company's development. The discovery of XD4241 and the subsequent identification of its mechanism of action validates our systems biology approach to drug discovery and demonstrates how it can rapidly and efficiently identify new drug leads." Xcellsyz's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Brad Hoy added, "We will continue to progress the XD4000 compound series through pre-clinical development using traditional drug development processes. This discovery is a firm foundation on which we will broaden and deepen our novel drug screening capabilities" Glycogen synthase glycogen synthase n. An enzyme that catalyzes the transfer of glucose from UDP-glucose to glycogen. kinase (GSK3) regulates glycogen synthase, the rate-limiting enzyme in glycogen synthesis. GSK3 has become a major target for pharmaceutical research and GSK3 inhibitors are currently being developed for the treatment of diabetes, stroke, bipolar disorder bipolar disorder, formerly manic-depressive disorder or manic-depression, severe mental disorder involving manic episodes that are usually accompanied by episodes of depression. and Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Each of these markets has a large unmet medical need, and have a potential combined market value of over $10 billion per year worldwide*. XCELLSYZ Xcellsyz is focused on the discovery of new drugs for diabetes and obesity through the use of novel cell-based technologies. The company has a unique approach for the creation of conditionally immortalized cell lines. Combined with the company's deep scientific expertise in diabetes and obesity, Xcellsyz' cell lines offer tremendous potential for the discovery and development of novel drugs. Xcellsyz cell lines also have wide potential applications in cell-based drug screening for other disease areas, for target discovery and validation, and in toxicity testing and drug metabolism studies. The value of Xcellsyz' approach has already been recognized and GSK, Novartis and Novo Nordisk have licenses to use certain Xcellsyz cell lines. Xcellsyz was founded in 2000 and has established state of the art cell biology facilities at the Bioscience Centre at the Centre for Life in Newcastle-Upon-Tyne. For more information, visit http://www.xcellsyz.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion